| [1] |
ANDERSEN JB, SPEE B, BLECHACZ BR, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors[J]. Gastroenterology, 2012, 142( 4): 1021－ 1031. DOI: 10.1053/j.gastro.2011.12.005. |
| [2] |
IYER P, CHEN MH, GOYAL L, et al. Targets for therapy in biliary tract cancers: The new horizon of personalized medicine[J]. Chin Clin Oncol, 2020, 9( 1): 7. DOI: 10.21037/cco.2019.12.11. |
| [3] |
LEE AJ, CHUN YS. Intrahepatic cholangiocarcinoma: The AJCC/UICC 8 th edition updates[J]. Chin Clin Oncol, 2018, 7( 5): 52. DOI: 10.21037/cco.2018.07.03. |
| [4] |
|
| [5] |
GUO XR, SHEN WZ. Latest evidence on immunotherapy for cholangiocarcinoma[J]. Oncol Lett, 2020, 20( 6): 381. DOI: 10.3892/ol.2020.12244. |
| [6] |
STROM BL, MAISLIN G, WEST SL, et al. Serum CEA and CA 19－9: Potential future diagnostic or screening tests for gallbladder cancer?[J]. Int J Cancer, 1990, 45( 5): 821－ 824. DOI: 10.1002/ijc.2910450505. |
| [7] |
TSUMURA T, DOI K, MARUSAWA H. Precision medicine of hepatobiliary and pancreatic cancers: Focusing on clinical trial outcomes[J]. Cancers, 2022, 14( 15): 3674. DOI: 10.3390/cancers14153674. |
| [8] |
CSOMA SL, BEDEKOVICS J, VERES G, et al. Circulating cell－free DNA－based comprehensive molecular analysis of biliary tract cancers using next－generation sequencing[J]. Cancers, 2022, 14( 1): 233. DOI: 10.3390/cancers14010233. |
| [9] |
ANGERILLI V, FORNARO L, PEPE F, et al. FGFR2 testing in cholangiocarcinoma: Translating molecular studies into clinical practice[J]. Pathologica, 2023, 115( 2): 71－ 82. DOI: 10.32074/1591－951X－859. |
| [10] |
KATOH M. Fibroblast growth factor receptors as treatment targets in clinical oncology[J]. Nat Rev Clin Oncol, 2019, 16( 2): 105－ 122. DOI: 10.1038/s41571－018－0115－y. |
| [11] |
NEUMANN O, BURN TC, ALLGÄUER M, et al. Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing[J]. Br J Cancer, 2022, 127( 8): 1540－ 1549. DOI: 10.1038/s41416－022－01908－1. |
| [12] |
USON JUNIOR PLS, BORAD MJ. Precision approaches for cholangiocarcinoma: Progress in clinical trials and beyond[J]. Expert Opin Investig Drugs, 2022, 31( 1): 125－ 131. DOI: 10.1080/13543784.2022.2017882. |
| [13] |
HELSTEN T, ELKIN S, ARTHUR E, et al. The FGFR landscape in cancer: Analysis of 4, 853 tumors by next－generation sequencing[J]. Clin Cancer Res, 2016, 22( 1): 259－ 267. DOI: 10.1158/1078－0432.CCR－14－3212. |
| [14] |
ABOU－ALFA GK, SAHAI V, HOLLEBECQUE A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open－label, phase 2 study[J]. Lancet Oncol, 2020, 21( 5): 671－ 684. DOI: 10.1016/S1470－2045(20)30109－1. |
| [15] |
JAVLE M, ROYCHOWDHURY S, KELLEY RK, et al. Infigratinib(BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open－label, single－arm, phase 2 study[J]. Lancet Gastroenterol Hepatol, 2021, 6( 10): 803－ 815. DOI: 10.1016/S2468－1253(21)00196－5. |
| [16] |
FENG YH, SU WC, OH DY, et al. Updated analysis with longer follow up of a phase 2a study evaluating erdafitinib in Asian patients(pts) with advanced cholangiocarcinoma(CCA) and fibroblast growth factor receptor(FGFR) alterations[J]. J Clin Oncol, 2022, 40( 4_suppl): 430. DOI: 10.1200/JCO.2022.40.4_suppl.430. |
| [17] |
GOYAL L, MERIC－BERNSTAM F, HOLLEBECQUE A, et al. Futibatinib for FGFR2－rearranged intrahepatic cholangiocarcinoma[J]. N Engl J Med, 2023, 388( 3): 228－ 239. DOI: 10.1056/NEJMoa2206834. |
| [18] |
SUN PK, MA TF, ZHANG TL, et al. Molecular basis for the function of the αβ heterodimer of human NAD－dependent isocitrate dehydrogenase[J]. J Biol Chem, 2019, 294( 44): 16214－ 16227. DOI: 10.1074/jbc.RA119.010099. |
| [19] |
MOLENAAR RJ, MACIEJEWSKI JP, WILMINK JW, et al. Wild－type and mutated IDH1/2 enzymes and therapy responses[J]. Oncogene, 2018, 37( 15): 1949－ 1960. DOI: 10.1038/s41388－017－0077－z. |
| [20] |
ABOU－ALFA GK, MACARULLA T, JAVLE MM, et al. Ivosidenib in IDH1－mutant, chemotherapy－refractory cholangiocarcinoma(ClarIDHy): A multicentre, randomised, double－blind, placebo－controlled, phase 3 study[J]. Lancet Oncol, 2020, 21( 6): 796－ 807. DOI: 10.1016/S1470－2045(20)30157－1. |
| [21] |
WU MJ, SHI L, MERRITT J, et al. Biology of IDH mutant cholangiocarcinoma[J]. Hepatology, 2022, 75( 5): 1322－ 1337. DOI: 10.1002/hep.32424. |
| [22] |
FRIEDLAENDER A, SUBBIAH V, RUSSO A, et al. EGFR and HER2 exon 20 insertions in solid tumours: From biology to treatment[J]. Nat Rev Clin Oncol, 2022, 19( 1): 51－ 69. DOI: 10.1038/s41571－021－00558－1. |
| [23] |
HARDING JJ, PIHA－PAUL SA, SHAH RH, et al. Antitumour activity of neratinib in patients with HER2－mutant advanced biliary tract cancers[J]. Nat Commun, 2023, 14( 1): 630. DOI: 10.1038/s41467－023－36399－y. |
| [24] |
HARDING J, CLEARY J, QUINN D, et al. Targeting HER2(ERBB2) mutation－positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT‘basket’ trial[J]. J Clin Oncol, 2021, 39( 3_suppl): 320. DOI: 10.1200/JCO.2021.39.3_suppl.320. |
| [25] |
JAVLE M, BORAD MJ, AZAD NS, et al. Pertuzumab and trastuzumab for HER2－positive, metastatic biliary tract cancer(MyPathway): A multicentre, open－label, phase 2a, multiple basket study[J]. Lancet Oncol, 2021, 22( 9): 1290－ 1300. DOI: 10.1016/S1470－2045(21)00336－3. |
| [26] |
MAIR MJ, BARTSCH R, LE RHUN E, et al. Understanding the activity of antibody－drug conjugates in primary and secondary brain tumours[J]. Nat Rev Clin Oncol, 2023, 20( 6): 372－ 389. DOI: 10.1038/s41571－023－00756－z. |
| [27] |
OHBA A, MORIZANE C, KAWAMOTO Y, et al. Trastuzumab deruxtecan(T－DXd; DS－8201) in patients(pts) with HER2－expressing unresectable or recurrent biliary tract cancer(BTC): An investigator－initiated multicenter phase 2 study(HERB trial)[J]. J Clin Oncol, 2022, 40( 16_suppl): 4006. DOI: 10.1200/JCO.2022.40.16_suppl.4006. |
| [28] |
AVRUCH J, KHOKHLATCHEV A, KYRIAKIS JM, et al. Ras activation of the Raf kinase: Tyrosine kinase recruitment of the MAP kinase cascade[J]. Recent Prog Horm Res, 2001, 56: 127－ 55. DOI: 10.1210/rp.56.1.127. |
| [29] |
SUBBIAH V, LASSEN U, ÉLEZ E, et al. Dabrafenib plus trametinib in patients with BRAF(V600E)－mutated biliary tract cancer(ROAR): A phase 2, open－label, single－arm, multicentre basket trial[J]. Lancet Oncol, 2020, 21( 9): 1234－ 1243. DOI: 10.1016/S1470－2045(20)30321－1. |
| [30] |
|
| [31] |
BAGCHI S, YUAN R, ENGLEMAN EG. Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance[J]. Annu Rev Pathol, 2021, 16: 223－ 249. DOI: 10.1146/annurev－pathol－042020－042741. |
| [32] |
CARLINO MS, LARKIN J, LONG GV. Immune checkpoint inhibitors in melanoma[J]. Lancet, 2021, 398( 10304): 1002－ 1014. DOI: 10.1016/S0140－6736(21)01206－X. |
| [33] |
XIE QF, WANG LD, ZHENG SS. Prognostic and clinicopathological significance of PD－L1 in patients with cholangiocarcinoma: A meta－analysis[J]. Dis Markers, 2020, 2020: 1817931. DOI: 10.1155/2020/1817931. |
| [34] |
PIHA－PAUL SA, OH DY, UENO M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE－158 and KEYNOTE－028 studies[J]. Int J Cancer, 2020, 147( 8): 2190－ 2198. DOI: 10.1002/ijc.33013. |
| [35] |
KIM RD, CHUNG V, ALESE OB, et al. A phase 2 multi－institutional study of nivolumab for patients with advanced refractory biliary tract cancer[J]. JAMA Oncol, 2020, 6( 6): 888－ 894. DOI: 10.1001/jamaoncol.2020.0930. |
| [36] |
LEE CK, CHON HJ, CHEON J, et al. Trastuzumab plus FOLFOX for HER2－positive biliary tract cancer refractory to gemcitabine and cisplatin: A multi－institutional phase 2 trial of the Korean Cancer Study Group(KCSG－HB19－14)[J]. Lancet Gastroenterol Hepatol, 2023, 8( 1): 56－ 65. DOI: 10.1016/S2468－1253(22)00335－1. |
| [37] |
BURRIS III HA, OKUSAKA T, VOGEL A, et al. Patient－reported outcomes for the phase 3 TOPAZ－1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer[J]. J Clin Oncol, 2022, 40( 16_suppl): 4070. DOI: 10.1200/JCO.2022.40.16_suppl.4070. |
| [38] |
Guidelines Working Committee of Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology(CSCO) Guidelines for Diagnosis and Treatment of Biliary Tract Malignancies 2022[M]. Beijing: People’s Medical Publishing House, 2022.
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)胆道恶性肿瘤诊疗指南2022[M]. 北京: 人民卫生出版社, 2022.
|
| [39] |
KELLEY RK, UENO M, YOO C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer(KEYNOTE－966): A randomised, double－blind, placebo－controlled, phase 3 trial[J]. Lancet, 2023, 401( 10391): 1853－ 1865. DOI: 10.1016/S0140－6736(23)00727－4. |
| [40] |
TANG ZH, CHEN JL, LIU SY, et al. Significance of combination of targeted therapy and immunotherapy in conversion therapy of biliary tract cancer[J]. Chin J Surg, 2022, 60( 4): 343－ 350. DOI: 10.3760/cma.j.cn112139－20220110－00019. |
| [41] |
YARCHOAN M, COPE L, RUGGIERI AN, et al. Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers[J]. J Clin Invest, 2021, 131( 24): e152670. DOI: 10.1172/JCI152670. |
| [42] |
COUSIN S, CANTAREL C, GUEGAN JP, et al. Regorafenib－avelumab combination in patients with biliary tract cancer(REGOMUNE): A single－arm, open－label, phase II trial[J]. Eur J Cancer, 2022, 162: 161－ 169. DOI: 10.1016/j.ejca.2021.11.012. |
DownLoad: